We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+13%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.5B
AUM Growth
+$923M
Cap. Flow
+$224M
Cap. Flow %
2.14%
Top 10 Hldgs %
34.54%
Holding
153
New
17
Increased
27
Reduced
30
Closed
10

Top Buys

Rank Stock Value
1
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$170M
2
AET
Aetna Inc
AET
+$79.5M
3
UHS icon
Universal Health Services
UHS
+$75.3M
4
KALA icon
KALA BIO
KALA
+$52.2M
5
IMMU
Immunomedics Inc
IMMU
+$50.5M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$185M
2
EW icon
Edwards Lifesciences
EW
+$51.3M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$50.6M
4
INSM icon
Insmed
INSM
+$48M
5
GKOS icon
Glaukos
GKOS
+$34.4M

Sector Composition

Rank Sector Weight
1 Healthcare 91.18%
2 Financials 2.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
$511M 4.89%
3,645,486
-226,300
-6% -$30.7M
BIIB icon
2
Biogen
BIIB
$32.1B
$510M 4.88%
1,630,000
– –
CELG
3
DELISTED
Celgene Corp
CELG
$489M 4.67%
3,351,977
-73,800
-2% -$10.1M
BSX icon
4
Boston Scientific
BSX
$68.9B
$391M 3.73%
13,397,000
-1,003,000
-7% -$27.7M
MRK icon
5
Merck
MRK
$325B
$351M 3.36%
5,750,376
– –
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$124B
$315M 3.01%
2,074,302
+47,800
+2% +$7.19M
PBYI icon
7
Puma Biotechnology
PBYI
$398M
$290M 2.78%
2,425,735
– –
LLY icon
8
Eli Lilly
LLY
$1.09T
$263M 2.51%
3,075,000
– –
REGN icon
9
Regeneron Pharmaceuticals
REGN
$73.1B
$256M 2.45%
572,770
+106,000
+23% +$50.4M
CI icon
10
Cigna
CI
$78.9B
$237M 2.26%
1,266,100
+44,000
+4% +$7.83M
AMGN icon
11
Amgen
AMGN
$212B
$234M 2.23%
1,253,100
-49,600
-4% -$8.79M
A icon
12
Agilent Technologies
A
$39.6B
$234M 2.23%
3,638,900
-175,200
-5% -$10.9M
WMGI
13
DELISTED
Wright Medical Group Inc
WMGI
$231M 2.21%
8,946,234
– –
AET
14
DELISTED
Aetna Inc
AET
$222M 2.12%
1,396,500
+508,600
+57% +$79.5M
CLVS
15
DELISTED
Clovis Oncology, Inc.
CLVS
$197M 1.88%
2,388,670
+284,300
+14% +$22.5M
ELV icon
16
Elevance Health
ELV
$82.8B
$176M 1.68%
927,618
+7,000
+0.8% +$1.33M
CMTA
17
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$176M 1.68%
+10,425,225
New +$170M
ABBV icon
18
AbbVie
ABBV
$471B
$175M 1.67%
1,965,000
-232,600
-11% -$17.7M
ARRY
19
DELISTED
Array Biopharma Inc
ARRY
$174M 1.67%
14,182,900
– –
INCY icon
20
Incyte
INCY
$25.3B
$172M 1.65%
1,476,000
-187,400
-11% -$23.7M
LOXO
21
DELISTED
Loxo Oncology, Inc
LOXO
$159M 1.52%
1,728,000
– –
GILD icon
22
Gilead Sciences
GILD
$166B
$156M 1.49%
1,928,000
-145,400
-7% -$11.1M
EW icon
23
Edwards Lifesciences
EW
$49.1B
$152M 1.45%
4,172,100
-1,345,800
-24% -$51.3M
JNJ icon
24
Johnson & Johnson
JNJ
$644B
$146M 1.4%
1,124,400
– –
IMMU
25
DELISTED
Immunomedics Inc
IMMU
$140M 1.34%
9,996,816
+5,067,858
+103% +$50.5M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2017 Portfolio in Review

As of Q3 2017, OrbiMed held 153 positions worth $10.5B, up 9.7% from $9.54B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q3 2017 filing shows 17 new, 27 increased, 30 reduced and 10 closed positions. Its largest new stake was Clementia Pharmaceuticals Inc.: 10,425,225 shares worth $176M. The largest sale was Humana, an estimated $185M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 93% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q3 2017 buy was Clementia Pharmaceuticals Inc.: 10,425,225 shares worth $176M.
  • OrbiMed added most to Aetna Inc in Q3 2017, an estimated $79.5M increase.
  • OrbiMed's biggest Q3 2017 reduction was Edwards Lifesciences, cutting an estimated $51.3M.
  • OrbiMed fully exited Humana in Q3 2017, selling an estimated $185M.
  • OrbiMed's ten largest holdings make up 35% of its $10.5B portfolio in Q3 2017.
  • OrbiMed opened 17 new positions and closed 10 in Q3 2017.
  • OrbiMed's portfolio value rose 9.7% quarter-over-quarter to $10.5B.

Based on OrbiMed's 13F filing for Q3 2017, filed 14 Nov 2017.